FDA Asks Pfizer - BioNTech To Submit For COVID-19 Vaccine Emergency Use Nod For Youngest Children

Pfizer Inc PFE and its partner BioNTech SE BNTX have started a rolling submission to amend its COVID-19 vaccine FDA Emergency Use Authorization (EUA) to include children six months to under five years of age.

  • With pediatric COVID-19 cases surpassing 10 million and at the request of the FDA, the companies have submitted available data on the safety and efficacy.
  • The application is for authorization of the first two 3 µg doses of a planned three-dose primary series in this age group. 
  • Data on a third dose given at least 8 weeks after the second dose are expected in the coming months and will be submitted to the FDA to support a potential expansion of EUA.
  • Pfizer announced that its vaccine (a 3 µg dose for the youngest population) demonstrated non-inferiority for the 6- to 24-month-old population, compared to the 16- to 25-year-old population in which high efficacy was demonstrated, but not for the 2- to under 5-year-old population.
  • “Ultimately, we believe that three doses of the vaccine will be needed for children 6 months through 4 years of age to achieve high levels of protection against current and potential future variants. If two doses are authorized, parents will have the opportunity to begin a COVID-19 vaccination series for their children while awaiting potential authorization of a third dose,” Pfizer CEO Albert Bourla said in a statement.
  • Price Action: PFE shares are down 0.19% at $53.07, while BNTX stock is up 1.11% at $181.60 during the premarket session on the last check Wednesday.
  • Photo by x3 from Pixabay
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLarge CapNewsHealth CareFDAGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!